STOCK TITAN

Invitation to the presentation of Calliditas´ Year-end report January - December 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Calliditas to release Year-end report for January - December 2023 with CEO and CFO participation. Webcast and conference call details provided.
Positive
  • None.
Negative
  • None.

STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday 21 February 2024 at 07.00 a.m. CET.

A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén.

The presentation will be given in English.

Link to the webcast: https://ir.financialhearings.com/calliditas-therapeutics-q4-report-2023 

To participate via conference call please register via this link: https://conference.financialhearings.com/teleconference/?id=50046870 

After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral questions.

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel. +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information was sent for publication, through the agency of the contact person set out above, on February 14, 2024, at 7:00 a.m. CET.

The following files are available for download:

https://mb.cision.com/Main/16574/3927985/2602135.pdf

Invitation to the presentation of Calliditas_Q4 2023

Cision View original content:https://www.prnewswire.com/news-releases/invitation-to-the-presentation-of-calliditas-year-end-report-january--december-2023-302061416.html

SOURCE Calliditas Therapeutics

Calliditas will release the Year-end report on Wednesday 21 February 2024 at 07.00 a.m. CET.

CEO Renée Aguiar-Lucander, CFO Fredrik Johansson, CMO Richard Philipson, and President North America Maria Törnsén will participate.

The presentation will be given in English.

To participate via conference call, register at the provided link to receive a phone number and conference ID.

For further information, contact Åsa Hillsten, Head of IR & Sustainability at Calliditas.
Calliditas Therapeutics AB

NASDAQ:CALT

CALT Rankings

CALT Latest News

CALT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Sweden
Stockholm

About CALT

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.